May 16, 2024 | Featured, Maryland, News, Science
PYC Therapeutics, an Australia-based developer of RNA therapies, reported initial results from its Phase 1 PLATYPUS clinical trial in the US for an RNA therapy known as VP-001 for people with retinitis pigmentosa 11 (RP11) which is caused by mutations in the gene...
May 16, 2024 | Media, News, Podcast
No serious adverse events were reported. One patient had encouraging improvement in retinal...
May 14, 2024 | Featured, Maryland, News, Science
A team of genetic researchers from the UK, US, and Switzerland has identified a mutation in the gene TMEM216 as a common cause of retinitis pigmentosa (RP) in people with African ancestry. The team estimates that approximately 20-30 percent of all RP patients with...
May 14, 2024 | Media, News, Podcast
The discovery will help geneticists diagnose more RP patients with African...
May 10, 2024 | Featured, Maryland, News, Science
EyeDNA Therapeutics, a subsidiary of Paris-based Coave Therapeutics, reported encouraging 24-month results for 17 adult patients in its Phase ½ PDE6B gene therapy clinical trial underway at Clinique Ophthalmologique, CHU de Nantes, in France. The results were reported...
May 10, 2024 | Media, News, Podcast
Mutations in PDE6B are a leading cause of retinitis...
